Trial Profile
A Prospective, Randomized, Multi-Center Study to Compare the Safety, Tolerability and Efficacy of Bevacizumab (Zydus Cadila) With Bevacizumab (Avastin®) in Non-Small Cell Lung Cancer (NSCLC)
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 16 Oct 2017
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Zydus Lifesciences
- 06 Sep 2016 New trial record
- 22 Aug 2016 Status changed from not yet recruiting to recruiting.